Form 4: Xeris Biopharma CEO Sells Shares After Option Exercise

Xeris Biopharma Holdings CEO and Director, John Patrick Shannon Jr., sold 24,907 shares of common stock after exercising multiple stock options.

Summary

• John Patrick Shannon Jr., CEO and Director of Xeris Biopharma Holdings, Inc. (XERS), reported transactions on January 5, 2026.
• He sold 24,907 shares of common stock at a weighted average price of $7.0766 per share, with prices ranging from $7.040 to $7.350.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan.
• He also exercised stock options to acquire a total of 92,301 shares of common stock.
• The exercised options included 64,265 shares at an exercise price of $1.55, 25,136 shares at an exercise price of $1.55, and 2,900 shares at an exercise price of $3.94.
• Following these transactions, his direct beneficial ownership of common stock increased to 2,797,647 shares.
• He retains 97,100 unexercised stock options with a strike price of $3.94, expiring on August 26, 2030.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there was an insider sale, it was pre-planned under a 10b5-1 plan, and the insider significantly increased their overall common stock holdings through option exercises, indicating continued confidence and a profitable transaction.

Positives

• The reporting person exercised stock options at significantly lower strike prices ($1.55 and $3.94) compared to the market sale price ($7.0766), indicating a profitable transaction.
• The sale of shares was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a scheduled, non-discretionary transaction rather than an opportunistic sale.
• Despite the sale, the insider's overall direct common stock holdings increased by 67,394 shares (92,301 acquired minus 24,907 sold) following the reported transactions, demonstrating continued equity interest.

Negatives

• The sale of 24,907 shares by a CEO and Director, even if pre-planned, represents a reduction in direct equity holdings from a previous level before the exercises.

Industry Context

This filing is a standard insider transaction report and does not provide specific industry context or relate to broader industry trends beyond the company's stock performance and executive compensation practices.

Stakeholder Impact

• Shareholders may interpret the insider's sale, even if pre-planned, as a signal, potentially influencing short-term stock price movements.
• The increase in direct common stock ownership by the CEO and Director could be viewed positively by shareholders as a sign of alignment with shareholder interests.

Key Dates

Keywords

Xeris Biopharma, XERS, insider trading, stock options, Form 4, CEO, director, share sale, Rule 10b5-1 plan